| Identification | Back Directory | [Name]
Trofinetide | [CAS]
853400-76-7 | [Synonyms]
NNZ-2566
Trofinetide
Trofinetide(NNZ2566)
TROFINETIDE; NNZ2566 ;NNZ 2566; NNZ-2566
L-Glutamic acid, glycyl-2-methyl-L-prolyl-
Trofinetide,NNZ 2566,NNZ2566,Inhibitor,inhibit | [Molecular Formula]
C13H21N3O6 | [MDL Number]
MFCD28502204 | [MOL File]
853400-76-7.mol | [Molecular Weight]
315.32 |
| Chemical Properties | Back Directory | [Melting point ]
144 °C | [Boiling point ]
655.4±55.0 °C(Predicted) | [density ]
1.377±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Methanol (Slightly), Water (Slightly) | [form ]
Solid | [pka]
3.51±0.10(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChI]
InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1 | [InChIKey]
BUSXWGRAOZQTEY-SDBXPKJASA-N | [SMILES]
C(O)(=O)[C@H](CCC(O)=O)NC(=O)[C@]1(C)CCCN1C(=O)CN |
| Hazard Information | Back Directory | [Uses]
Trofinetide is a synthetic analogue of the endogenous N-terminus tripeptide, Glycine-Proline-Glutamate (GPE), that has shown to be neuroprotective in animal models of brain injury. | [in vivo]
Trofinetide (NNZ-2566) suppresses penetrating ballistic-like brain injury (PBBI) induced inflammatory cell infiltration at 3 days following PBBI as compare to vehicle treatment. Trofinetide treatment significantly reduces the elevation of IL-6 (79%), E-selectin (81%), IL-1β (76%) and TNF-α (72%) mRNA levels in the injured hemisphere at 12 h post-PBBI, with maximal inhibition occurring between 12 h and 24 h. Trofinetide treatment does not affect the PBBI-induced up-regulation of IL-6 expression at any time point, but does produce significant reductions in the injury-induced up-regulation of IL-1β, INF-γ, and TNF-α expression. Trofinetide treatment suppresses IL-1β expression in the injured brain hemisphere for up to 7 days post-PBBI[1]. The high doses of Trofinetide (NNZ-2566) (10 and 100 mg/kg bolus followed by continuous infusion) attenuate non-convulsive seizure (NCS) occurring beyond 2 h after permanent middle cerebral artery occlusion (pMCAo). All doses of Trofinetide completely suppress the delayed occurrence of NCS as compare with the vehicle-treated animals[2]. | [storage]
Store at -20°C |
|
|